Faster Acquisition of Overseas Approvals and Expansion of Sales Regions and Product Offerings
First written in FY2016. 3 of 6 entries say "Restated". Latest entry: FY2024.
- FY2024RestatedAnnual report
「The company intends to further strengthen its regulatory application systems for selling its products worldwide.」
The company continues to outline its policy of strengthening its regulatory application systems for sales in each country. - FY2023AdvancedAnnual report
「“ビューティボンド Xtreme” obtained approval under Europe’s new MDR (Medical Device Regulation) in August 2022 and was exhibited at IDS (International Dental Show), the world’s largest dental trade show, held in Cologne, Germany, in March 2023.」
“ビューティボンド Xtreme” obtained European MDR approval and was exhibited at IDS in March 2023. - FY2021RestatedAnnual report
「The company will accelerate the development of new products suited to each sales region, while strengthening its response to regulations worldwide and its systems for filing approval applications to sell its products.」
The company continues to outline faster product development by sales region, responses to the regulations of each country, and the strengthening of its approval application systems. - FY2019RestatedAnnual report
「Overseas, the company will launch new products and pursue proactive sales expansion activities, while developing and expanding sales systems suited to the regulatory requirements of each country.」
The company continues to outline the launch of new products overseas, sales expansion, and the development of sales systems suited to the regulatory requirements of each country. - FY2018WorsenedAnnual report
「Delays in developing the overseas sales network and responding to pharmaceutical regulations in each country」
Delays in responding to regulatory requirements in each country are cited as one factor that made it difficult to achieve the target for the fiscal year ending March 2022. - FY2016First statedAnnual report
「Overseas, in addition to developing its sales network and sales bases, the company will accelerate the acquisition of approvals required to sell its products in each country and work to expand its product offerings and sales regions.」
The company has indicated a policy of expanding its product offerings and sales regions by accelerating regulatory approvals in each country, in addition to developing its overseas sales network.